A vaccine developed by AstraZeneca and the University of Oxford prevented 70% of people from developing the coronavirus in late-stage trials, the team reported Monday.
The study, published in The Lancet medical journal, suggest that those aged over 70 -- who are at higher risk of serious illness and death from Covid-19 -- could build robust immunity to the novel Coronavirus.
